课题基金 / 基金详情

SHP-1 REGULATION OF THE KU SIGNALING PATHWAY

SHP-1 REGULATION OF THE KU SIGNALING PATHWAY
SHP-1 对 KU 信号通路的调节
批准号:
6627286
负责人:
Taolin Yi
金额:
$16.32万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-01-01 至 2003-12-31

项目摘要

项目成果

Taolin Yi的其他基金

相似基金

相关文献

中文摘要
翻译
描述:(改编自申请人的摘要) 该应用程序描述了研究机制 蛋白质酪氨酸调节细胞生长的基础 磷酸酶SHP-1。 SHP-1 是一种含有 SH2 结构域的酪氨酸磷酸酶 已在许多系统中显示出负面监管 受体介导的细胞信号传导途径,因此负面影响 调节细胞生长。它在以下领域得到了最广泛的研究 造血/细胞因子受体、FCgRIIB 和 MCH I 类的背景 NK 细胞上表达的受体,其中 SHP-1 被招募到 酪氨酸磷酸化受体并被激活。调查员有 鉴定出与 SHP-1 相关的核蛋白 证明 SHP-1 存在于细胞核中。易博士建议 研究:1)两个C端酪氨酸残基在 SHP-1的核定位; 2) 细胞周期依赖性 SHP-1 与其核结合伙伴的相互作用; 3)角色 这些结合伙伴在激活磷酸酶活性中的作用 SHP-1。通过这些研究,研究者建议确定一个 SHP-1 的核功能有助于其发挥负面作用 细胞生长的调节剂。
英文摘要
DESCRIPTION: (Adapted from the applicant's abstract) This application describes studies to investigate the mechanism underlying the regulation of cell growth by the protein tyrosine phosphatase SHP-1. SHP-1 is a SH2-domain containing tyrosine phosphatase that has been shown in a number of systems to negatively regulate receptor-mediated cell signaling pathways and therefore negatively regulate cell growth. It has been most extensively studied in the context of hematopoietic/cytokine receptors, FCgRIIB and MCH class I receptors expressed on NK cells, where SHP-1 is recruited to the tyrosine phosphorylated receptor and activated. The investigator has identified nuclear proteins that are associated with SHP-1 and has demonstrated that SHP-1 is found in the nucleus. Dr. Yi proposes to investigate: 1) the role of two C-terminal tyrosine residues in the nuclear localization of SHP-1; 2) the cell cycle dependence on the interaction of SHP-1 with its nuclear binding partners; and 3) the role of these binding partners in activating the phosphatase activity of SHP-1. Through these studies the investigator proposes to identify a nuclear function for SHP-1 that contributes to its role as a negative regulator of cell growth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Anti-Cancer Activities of PTPase Inhibitors
Anti-Cancer Activities of PTPase Inhibitors
Anti-Cancer Activities of PTPase Inhibitors
PTPases as Therapeutic Targets
海外基金